S
Susan M. Domchek
Researcher at University of Pennsylvania
Publications - 501
Citations - 37655
Susan M. Domchek is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 83, co-authored 439 publications receiving 30495 citations. Previous affiliations of Susan M. Domchek include Brigham and Women's Hospital & Cancer Council Victoria.
Papers
More filters
Proceedings ArticleDOI
Abstract P4-22-14: Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer
AS Clark,X Wang,Andrea B. Troxel,Jessica A. Burrell,Michael Feldman,Priti Lal,Paul J. Zhang,Mark A. Rosen,Maryann Gallagher,John Ndicu,Isoris Nivar,Jennifer M. Matro,Susan M. Domchek,Kevin Fox,Peter O'Dwyer,AM DeMichele +15 more
TL;DR: P is well tolerated in heavily pretreated pts and required dose reduction without necessity to add growth factor support; febrile ntp was uncommon in a pt who was progressing and had received 13 prior therapies.
Journal ArticleDOI
EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer.
Bryson W. Katona,Jessica M. Long,Nuzhat A. Ahmad,Sara Attalla,Angela R. Bradbury,Erica L. Carpenter,Dana Farengo Clark,Gillain Constantino,Koushik K. Das,Susan M. Domchek,Christina M. Dudzik,Jessica Ebrahimzadeh,Gregory G. Ginsberg,Jordan Heiman,Michael L. Kochman,Kara N. Maxwell,Danielle McKenna,Jacquelyn Powers,Payal D. Shah,Kirk J. Wangensteen,Anil K. Rustgi +20 more
TL;DR: In this article, the authors investigated outcomes of endoscopic ultrasound (EUS)-based PDAC surveillance in BRCA1/BRCA2/ATM/PALB2 carriers without a family history of PDAC.
Proceedings ArticleDOI
Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Mark E. Robson,Seock-Ah Im,Elżbieta Senkus,Binghe Xu,Susan M. Domchek,Norikazu Masuda,Suzette Delaloge,Wei Li,Nadine Tung,Anne C Armstrong,Wendy Bannister,C. Goessl,A. Allen,Pierfranco Conte +13 more
TL;DR: With extended follow-up, OS did not differ significantly between treatment arms; however, continued OS benefit was suggested for olaparib versus chemotherapy for patients in the first-line setting for mBC, with no new safety findings over long-term treatment.
Journal ArticleDOI
Clinical implications of low-penetrance breast cancer susceptibility alleles.
TL;DR: Current understanding of low-penetrance genes is reviewed, with a specific focus on their clinical implications, and the availability of new techniques such as genome-wide association studies ensures that more low-risk alleles will be identified.
Proceedings ArticleDOI
Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts
Susan M. Domchek,Sophie Postel-Vinay,S-A. Im,Y Hee Park,J.-P. Delord,Antoine Italiano,Jérôme Alexandre,Benoit You,S Bastian,Matthew G Krebs,S. Waqar,M. Lanasa,Helen K. Angell,M Tang,C. Gresty,L Opincar,P. Herbolsheimer,Bella Kaufman +17 more
TL;DR: Evidence suggests that mutations in other homologous recombination repair (HRR) genes may confer a BRCA-like phenotype, warranting an expansion of the study population beyond BRCAm, and MEDIOLA is a Ph I/II open-label, multicenter study enrolling patients across several tumor types.